TOP >>Main Part 2012 >>2-2 >>Urology
Urology |
Director GOTOH, Momokazu (Professor) 10E |
Extensive achievements and expertise to treat patients with various diseases |
We provide comprehensive medical care including diagnosis and treatment of urogenital (kidney, ureter, bladder, urethra, prostate, penis, and testis) disease. |
One professor (Director), one associate professor, two assistant professors, six lecturers, and five doctors provide medical care. Outpatient days are Monday through Friday. Surgery days are Monday, Tuesday, Thursday, and Friday.
Benign and malignant tumors within the scope of our department, congenital malformation, all functional and organic diseases, diseases in the field of female urology (pelvic organ prolapse), urinary disturbances (neurogenic bladder, prostatic hyperplasia, and urinary incontinence), sexual and reproductive diseases including gender identity disorder and male infertility, and urinary calculus.
Laparoscopic surgery and robotic surgery for urogenital cancer (e.g. renal cancer, prostate cancer), brachytherapy for prostate cancer, surgical treatment of pelvic organ prolapse and stress urinary incontinence, renal transplantation, medical care for urinary disturbances including neurogenic bladder, prostatic hyperplasia, and urinary incontinence, urinary calculus, and cancer chemotherapy.
The daily number of outpatients is 120 to 150; the daily average number of inpatients is 33; the annual number of surgeries is 550 (of those, 150 are laparoscopic surgeries [surgery for renal cancer: 80, surgery for prostate cancer: 60]), the annual number of renal transplantations is 10; the annual number of brachytherapy procedures (for prostate cancer) is 45.
In addition to medical care in the general outpatient clinic, we provide medical care in the specialized outpatient clinics for renal transplantation, urinary incontinence, impaired urination, and prostate cancer.
For advanced medicine, we perform robotic surgery of prostate cancer, laparoscopic retroperitoneal lymph node dissection for testicular cancer, and bladder hydrodistention for interstitial cystitis. We conduct clinical studies on cell therapy for urinary incontinence using adipose-derived stem cells.